TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3902199
Drug: Cisplatin (CACP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CACP) + 5-fluorouracil (5-FU) bolus (CACP 100 mg/m2 day 1 and 5-FU 600 mg/m2 day 1 and day 8)
Study: 3902199
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + 5-FU infusion
Study: 21037028
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with accelerated functional rehabilitation
Study: 21037028
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with accelerated functional rehabilitation
Study: 12505552
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment for insomnia
Study: 12505552
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no psychological treatment)
Study: 10211848
Drug: Zinc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (25 mg)
Study: 548558
Drug: PGF2 alpha
Normalized name: Prostaglandin PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha gel
Study: 6575575
Drug: PGE2 tablets
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 tablets
Study: 21383110
Drug: Low MPH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low MPH dose
Study: 21383110
Drug: High MPH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High MPH dose
Study: 19823178
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg once daily for 6 weeks
Study: 19823178
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg once daily for 6 weeks in group I (ED)
Study: 19823178
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg once daily for 6 weeks in group II (no ED)
Study: 11504824
Drug: Thalidomide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide, 200 mg daily
Study: 9011704
Drug: Warm bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm bypass (37 degrees C, hematocrit 23%, pump flow 150 ml/kg per minute)
Study: 9011704
Drug: Hypothermic low-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic low-flow bypass (75 ml/kg per minute)
Study: 8215281
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg orally)
Study: 8215281
Drug: Ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (250 mg intramuscularly)
Study: 2894217
Drug: ICI 118551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551 (150 mg daily for 7 days)
Study: 2894217
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg daily for 7 days)
Study: 20584877
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg x 1 x IV + 90 mg x 1 x day V-VII
Study: 20584877
Drug: Tramadol sustained-release
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol sustained-release 100 mg x 2 x VII
Study: 10394873
Drug: 2400 mg
Normalized name: pancreatin 2400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg of ferric ammonium citrate
Study: 9116394
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate (300 mg/day for 4 weeks every 4 months)
Study: 9116394
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate (150 mg/day for 4 weeks every 2 months)
Study: 6657002
Drug: Nomifensine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (200 mg orally)
Study: 28125735
Drug: Real-time fMRI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time fMRI neurofeedback training (4 weekly sessions, 60-min each)
Study: 23429593
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg aflibercept, 1-hour intravenous
Study: 14505296
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg/d)
Study: 14505296
Drug: Sertraline (147
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (147 mg)
Study: 10381787
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day meloxicam
Study: 6296755
Drug: Individual vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual vaccines
Study: 28375032
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of dalteparin sodium (DS)
Study: 28375032
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of dalteparin sodium (DS)
Study: 11592727
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation (4.2 g/d)
Study: 11897986
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg intranasally once daily)
Study: 11897986
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg orally once daily)
Study: 7573647
Drug: Open kinetic
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open kinetic chain exercises using conventional physical therapy equipment
Study: 2110972
Drug: IFN-gamma (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-gamma (0.03 mg/m2, 0.3 mg/m2, 1 mg/m2, 3 mg/m2)
Study: 506644
Drug: 8 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 grams of lecithin administered orally
Study: 506644
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of placebo administered orally
Study: 30653242
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg/day for 4 weeks
Study: 19658274
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion for 10-14 days
Study: 19658274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnesium sulfate infusion)
Study: 16675938
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg/kg initial dose, 0.03 mg/kg maintenance)
Study: 16675938
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg/kg initial dose, 0.02 mg/kg maintenance)
Study: 12145008
Drug: High-isoflavone soyfood
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone soyfood diet (50 g soy protein and 73 mg isoflavones daily)
Study: 12145008
Drug: Low-isoflavone soyfood
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone soyfood diet (52 g soy protein and 10 mg isoflavones daily)
Study: 26867046
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care consisting of chemotherapy followed by endocrine therapy.
Study: 26867046
Drug: Oncotype DX
Normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncotype DX test used to assign patients to treatment.
Study: 26867046
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care if 'recurrence score' (RS) was > 25 or endocrine therapy alone if RS was ≤ 25.
Study: 20054285
Drug: Nonbismuth quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbismuth quadruple therapy
Study: 16382603
Drug: 3D displays
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D displays with appropriate cues (e.g., shadows)
Study: 10218722
Drug: Propranolol, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 160 mg/day (n = 37)
Study: 10218722
Drug: Atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 100 mg/day (n = 38)
Study: 10218722
Drug: Bisoprolol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol, 10 mg/day (n = 39)
Study: 10218722
Drug: Celiprolol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol, 400 mg/day (n = 38)
Study: 2213773
Drug: Clotrimazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (20 mg/kg/day) 2 days a week for 12 weeks
Study: 31347385
Drug: Cediranib alongside
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib alongside chemotherapy followed by placebo maintenance (arm B)
Study: 31347385
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during chemotherapy and maintenance (arm A)
Study: 29273007
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
Study: 26673577
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2
Study: 17868430
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg q.d.
Study: 17868430
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg b.i.d.
Study: 17868430
Drug: Apixaban 20
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 20 mg b.i.d.
Study: 17868430
Drug: Warfarin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (titrated to INR 1.8-3.0)
Study: 17868430
Drug: Apixaban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (all doses)
Study: 15135472
Drug: Sentinel node
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel node biopsy (SNB) using a peritumoural injection technique with blue dye and radiolabelled colloid mapping
Study: 15135472
Drug: Standard axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard axillary treatment after SNB
Study: 12503706
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 microg, twice daily for 12 weeks
Study: 26333499
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 g/(kg.h) for 10 min, then 0.3 g/(kg.h) for 20 min)
Study: 26333499
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg for 60 s, then 0.04 mg/(kg.h) for 20 min)
Study: 22940561
Drug: BZDs concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZDs concurrent with opioids
Study: 22940561
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BZDs and opioids
Study: 11297596
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg) plus Vitamin D(3) (800 IU)
Study: 31606265
Drug: Anti-IL-17A treatment
Normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-17A treatment
Study: 24907778
Drug: Receiving multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving multiple HIV prevention messages (about PrEP, nPEP, rectal microbicides, and condoms)
Study: 18720689
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily plus oral levamisole 2.5 mg/kg/wk (up to 150 mg/wk)
Study: 12462431
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (AMX/CA) 875/125 mg b.i.d. for 14 days
Study: 12462431
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg b.i.d. for 14 days
Study: 7729023
Drug: Shock or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock or antitachycardia pacing therapy
Study: 1781288
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (0.05 mg bid for 4 weeks for multi-infarct dementia; 0.03 mg bid for 2 weeks for senile and presenile simple memory disorders)
Study: 6452948
Drug: two‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: two‐ and three‐drug combinations
Study: 6452948
Drug: three treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: three treatment regimens
Study: 31651370
Drug: Etelcalcetide (ETL)
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etelcalcetide (ETL) administered intravenously after every hemodialysis session for 12 months
Study: 31651370
Drug: Alfacalcidol administered
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol administered intravenously after every hemodialysis session for 12 months
Study: 27678271
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (20 mL of 0.5% bupivacaine)
Study: 27678271
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (20 mL of 0.9% normal saline)
Study: 25251885
Drug: Optimized Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized Oral Methadone (OOM)
Study: 24052362
Drug: Metoprolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (5-10 mg)
Study: 23044558
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone ointment used twice a day for the first month and then once a day for 6 months on a few grafted lesions
Study: 17420168
Drug: High-GDP PD
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-GDP PD solution
Study: 17420168
Drug: Low-GDP PD
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-GDP PD solution
Study: 15689069
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg body weight dihydroartemisinin (DHA)
Study: 15689069
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg body weight dihydroartemisinin (DHA)
Study: 15689069
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg body weight oral artesunate (AS)
Study: 15689069
Drug: oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral artesunate (AS)
Study: 7535990
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (400 ml per day, 11% alcohol)
Study: 7535990
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (400 ml per day, 11% alcohol)
Study: 3239522
Drug: OK432 intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK432 intradermal administration
Study: 28845931
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (Control)
Study: 30662331
Drug: Combination panel
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination panel of ALT, HOMA-IR, and RBP4
Study: 25801553
Drug: 15.0 mg
Normalized name: RUXOLITINIB 15.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.0 mg of sublingual artemether (5 × 3.0 actuations)
Study: 25801553
Drug: 30.0 mg
Normalized name: PETROLATUM 30.0 mg in 1 g TOPICAL STICK [Winco Medicated Lip Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.0 mg of sublingual artemether (10 × 3.0 mg)
Study: 25801553
Drug: 30.0 mg
Normalized name: PETROLATUM 30.0 mg in 1 g TOPICAL STICK [Winco Medicated Lip Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.0 mg of sublingual artemether (5 × 6.0 mg)
Study: 25801553
Drug: 30.0 mg
Normalized name: PETROLATUM 30.0 mg in 1 g TOPICAL STICK [Winco Medicated Lip Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.0 mg of artemether in tablet form
Study: 25801553
Drug: 30.0 mg
Normalized name: PETROLATUM 30.0 mg in 1 g TOPICAL STICK [Winco Medicated Lip Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30.0 mg of sublingual artemether given over 5 days as either 10 3.0‐mg or 5 6.0‐mg actuations
Study: 23711188
Drug: Sitagliptin daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin daily for 28 days
Study: 21850387
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg, range 10-40 mg)
Study: 19272375
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 250 mg naproxen
Study: 19272375
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 50 mg diclofenac
Study: 19272375
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1 g acetaminophen
Study: 15709456
Drug: Montelukast (MON;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (MON; 10 mg daily)
Study: 15709456
Drug: Zafirlukast (ZAF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (ZAF; 40 mg daily)
Study: 9737821
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral controlled release tablet (A)
Study: 9737821
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg aqueous solution retained in the mouth for 10 min (B)
Study: 9737821
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg bioadhesive buccal tablet placed between the lower gum and lip for 6 h (C)
Study: 7856622
Drug: Venlafaxine (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-375 mg/day in two or three divided doses)
Study: 2563045
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (30 cm2 for heavy smokers, 20 cm2 for others)
Study: 30817455
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sokolow‐Lyon index, Cornell voltage duration product, and/or Romhilt‐Estes score at least 4
Study: 17909129
Drug: Family-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based intervention (22 weekly group sessions for parents and preschoolers and 10 biweekly home visits over 6-8 months)
Study: 15049991
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of 1% testosterone gel applied once or twice daily
Study: 15049991
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of 2% testosterone gel applied once daily
Study: 15049991
Drug: 2% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% testosterone gel applied once daily
Study: 15049991
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of 2% testosterone gel applied once or twice daily
Study: 11574416
Drug: Hypoglycemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-unaware patients
Study: 11574416
Drug: Hypoglycemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-aware patients
Study: 9663185
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg S(+)-ibuprofen
Study: 9663185
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg S(+)-ibuprofen
Study: 9663185
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg racemic ibuprofen
Study: 7816992
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg qid)
Study: 3661614
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g twice daily
Study: 21786177
Drug: Vernakalant 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant 3 mg/kg IV infusion
Study: 21786177
Drug: Vernakalant 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant 2 mg/kg IV infusion
Study: 16869719
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with anastrozole and tamoxifen
Study: 12950664
Drug: CQ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ treatment of CQ-S infections
Study: 12950664
Drug: CQ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ treatment of CQ-R infections
Study: 7675863
Drug: Flumazenil (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (5.0 mg/70 kg)
Study: 7675863
Drug: Flumazenil (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.25, 0.5, and 1.0 mg/70 kg)
Study: 2142633
Drug: Low-dose sufentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sufentanil (0.5 micrograms.kg‐1) with lidocaine (1.5 mg.kg‐1)
Study: 2142633
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (C)
Study: 7383457
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal suppositories
Study: 25667811
Drug: Pharmacist comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist comprehensive medication management services (PCS)
Study: 25667811
Drug: No pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacist comprehensive medication management services (NCS)
Study: 23063027
Drug: Regular sliding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular sliding scale insulin (SSI) (n = 173)
Study: 23063027
Drug: Impaired kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired kidney function (glomerular filtration rate < 60 ml/min)